Cagrilintide
An experimental long-acting amylin analog taken weekly, studied alone and paired with semaglutide (CagriSema).
- Evidence
- Ongoing clinical research
- Half-life
- ~7 days
- Sources
- 3 cited
Is cagrilintide FDA-approved?
Investigational. Not FDA-approved.
Overview
Amylin is a hormone your pancreas releases with insulin after meals; it helps you feel full. Cagrilintide is a long-acting version. In a 26-week phase 2 trial, the highest dose led to about 11% weight loss, versus 3% on placebo and 9% on liraglutide.
How it works
It acts on amylin and calcitonin receptors in the brain to increase fullness and slow the stomach. It works through a different pathway from GLP-1, which is why it's being combined with semaglutide.
How long does cagrilintide stay in the body?
About 7–8 days (159–195 hours) in early human studies. Levels peak 1–3 days after a shot.
What it's studied for
- Weight management
- Combination with semaglutide (CagriSema)
Reported side effects
- Nausea, constipation, diarrhea
- Injection-site reactions
Related: Retatrutide, CagriSema, Lixisenatide, Survodutide.
Sources
The studies and prescribing labels this page is written from.
- Once-weekly cagrilintide for weight management: a dose-finding phase 2 trial. Lancet, 2021 PubMed
- Cagrilintide with semaglutide: a phase 1b trial. Lancet, 2021 PubMed
- Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem, 2021 PubMed
